Both ingredients are associated with improved mitochondrial function
Approximately 6.5 million Americans have heart failure, a number projected to increase by 8 million by 2030. About half of those patients have heart failure with preserved ejection fraction (HFpEF). A new paper published in The Annals of Medicine and Surgery Journal (Lond) describes the potential use of d-ribose and ubiquinol for managing HFpEF, and a study to confirm those benefits.
Funding for the paper, “ Potential use of ubiquinol and d-ribose in patients with heart failure with preserved ejection fraction ,” by Janet D. Pierce, et.al., University of Kansas Medical Center, was provided by the National Institutes of Health, National Institute on Aging and the Department of Health and Human Services. The paper reviews the role of mitochondrial metabolism as it may
relate to HFpEF pathophysiology and the potential mechanisms by which ubiquinol and d-ribose may impact mitochondrial function.